The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

På svenska

Author

  • Fortunato Morabito
  • Sara Bringhen
  • Alessandra Larocca
  • Pierre Wijermans
  • Maria Victoria Mateos
  • Peter Gimsing
  • Carla Mazzone
  • Daniela Gottardi
  • Paola Omede
  • Sonja Zweegman
  • Juan Jose Lahuerta
  • Renato Zambello
  • Pellegrino Musto
  • Valeria Magarotto
  • Martijn Schaafsma
  • Albert Oriol
  • Gunnar Juliusson
  • Chiara Cerrato
  • Lucio Catalano
  • Massimo Gentile
  • Ana Isabel Turel
  • Anna Marina Liberati
  • Maide Cavalli
  • Davide Rossi
  • Roberto Passera
  • Stefano Rosso
  • Meral Beksac
  • Michele Cavo
  • Anders Waage
  • Jesus San Miguel
  • Mario Boccadoro
  • Pieter Sonneveld
  • Antonio Palumbo
  • Massimo Offidani
Show all

Summary, in English

Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide (MPT) are lacking. Nine hundred and fifty-six elderly (>65 years) newly diagnosed MM patients from six European randomized trials were retrospectively analyzed and matched for age, albumin, and beta2-microglobulin at diagnosis, 296 patients were selected from the VMP groups, and 294 from MPT. Complete response rate was 21% in the VMP patients and 13% in the MPT patients (P=0.007). After a median follow-up of 34 months (range, 1-92), VMP significantly prolonged both PFS (median 32.5 vs. 22.9 months, HR 0.65; 95% CI 0.52-0.82; P<0.001) and OS (median 79.7 vs. 45.1 months, HR 0.44; 95% CI 0.32-0.59; P<0.001) in comparison with MPT. The benefit in terms of OS of the VMP group was quite similar among patients with different risk factors defined by sex, ISS, ECOG performance status, or serum creatinine but not among patients 75 years. Multivariate analysis confirmed that VMP was an independent predictor of longer PFS and OS. In a control-case matched analysis, PFS and OS were prolonged in patients who received VMP in comparison with those treated with MPT. Am. J. Hematol. 89:355-362, 2014. (c) 2013 Wiley Periodicals, Inc.

Department/s

  • Stem Cell Center
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation

Publishing year

2014

Language

English

Pages

355-362

Publication/Series

American Journal of Hematology

Volume

89

Issue

4

Document type

Journal article

Publisher

John Wiley & Sons Inc.

Topic

  • Hematology

Status

Published

ISBN/ISSN/Other

  • ISSN: 0361-8609